Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction

GlaxoSmithKline PLC

www.gsk.com

Latest From GlaxoSmithKline PLC

Bookmark
  • Analysis

Behave, Pharma: Why Culture Is Top Of The List

By Melanie Senior

Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.

Outlook 2020 Leadership
Bookmark
  • News

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

By Michael Cipriano

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review
Bookmark
  • News

Sanofi Personalizing IBS Treatment With Digital Therapy

By Tom Gallen
Sanofi Consumer Healthcare has teamed up with digital health player Cara Care to offer an innovative treatment for IBS which goes beyond the pill and helps sufferers access personalized support for their illness.
Digital Health Innovation
Bookmark
  • Analysis

J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

By Mandy Jackson

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

Cancer Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By